CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
Triheptanoin +1 moredrug
Likely dose
Triheptanoin 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03642860
NCT03642860Phase 2Completed

Triheptanoin's Effect on Fatty Acid Oxidation and Exercise Tolerance in Patients With Debrancher Deficiency, Glycogenin-1 Deficiency and Phosphofructoinase Deficiency at Rest and During Exercise. A Randomized, Double-blind, Placebo-controlled, Cross-over Study

Rigshospitalet, Denmark·interventional·Posted Aug 22, 2018·Updated Feb 22, 2024

In Brief

A Phase 2 clinical trial evaluating Triheptanoin and Placebo Oil for Tarui Disease and 2 related conditions. Completed, enrolled 3 participants across 1 site.

Detailed Summary

The aim of this study is to investigate the effect of 14 days of treatment with the dietary oil-supplement Triheptanoin on fat metabolism and exercise tolerance in patients with Phosphofructokinase deficiency, Debrancher deficiency and Glycogenin-1 deficiency. The investigators wish to investigate whether a Triheptanoin diet can improve exercise capacity by measuring: 1. Heart rate during cycling exercise and maximal exercise capacity 2. Fat and glucose metabolism 3. Concentrations of metabolic substrates in blood during exercise 4. Perception of fatigue and symptoms by questionnaire 5. Degree of exhaustion during cycling exercise by Borg score All measurements are done before and after 14 days with a Triheptanoin-oil diet, and before and after 14 days diet with safflower (Placebo-oil). Triheptanoin-oil supplementation in the diet has been shown to increase metabolism of both fat and carbohydrates in patients with other metabolic myopathies. In these patients, Triheptanoin improved physical performance and has reduced the amount of symptoms experienced by patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 22, 2018
Enrollment StartAug 15, 2018
Primary CompletionAug 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.9 years ago

Interventions

Triheptanoindrug

Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).

Placebo Oildrug

Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).